ArticleBMC biotechnology2025
Gellan gum/gelatin Schiff-base hydrogel for ocular drug delivery of timolol maleate.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recent Advances in Extended Ocular Drug Delivery for the Ocular Surface.Molecules (Basel, Switzerland) · 2026Review
- Review
- Ion‑Responsive in situ Gel of Quercetin‑Loaded PEGylated Liposomes for Anti‑inflammatory Treatment of Dry Eye Disease.International journal of nanomedicine · 2026Article
- Bridging Preclinical and Clinical Gaps in Ocular Therapeutics: Hydrogel Drug Delivery and 3D Tissue Models.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In ocular drug delivery, increasing the retention time of the drug by using in situ forming hydrogels can be effective. In the current study, hydrogels with suitable gelling properties were obtained using oxidized gellan gum as a green crosslinker and gelatin via Schiff-base linkages. In the first step, oxidation of gellan gum was done to obtain aldehyde groups, and in situ gelling hydrogels were formed based on a simplistic Schiff-base reaction between oxidized gellan gum and amine groups of gelatin in the presence of β-glycerophosphate disodium salt as a pH adjustment agent and gelation accelerator. The calculated aldehyde content was about 64.5% by the titration method. By optimizing the concentration of gelatin, oxidized gellan gum, and β-glycerophosphate disodium salt, hydrogels with a fast gelation time were obtained. The synthesized hydrogels were investigated via Fourier-transform infrared (FT-IR) spectroscopy, scanning electron microscope (SEM), X-ray diffraction (XRD), swelling degree, and rheological properties. The effect of oxidized gellan gum and gelatin concentration on the physical and chemical characteristics of the obtained hydrogel system were studied. The results of in vitro and ex vivo research indicated that the prepared hydrogel with a high concentration of oxidized gellan gum and gelatin had a higher release rate, stronger network, and homogeneous morphological structure. The synthesized hydrogels have adequate porosity for drug loading (around 98-99%). Also, the MTT cytotoxicity test on bone marrow mesenchymal stem cells (BMSCs) confirmed that the developed hydrogels with green crosslinker do not have cytotoxic effects. In vitro and ex vivo drug release tests demonstrated a facile preparation strategy for fast-gelling hydrogels that can be considered as an appropriate candidate for timolol maleate delivery in glaucoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.